Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib.
about
Structural complex of sterol 14 -demethylase (CYP51) with 14 -methylenecyclopropyl- 7-24, 25-dihydrolanosterolMechanism-based inactivation of CYP450 enzymes: a case study of lapatinibTAMH: A Useful In Vitro Model for Assessing Hepatotoxic MechanismsHepatocellular Toxicity Associated with Tyrosine Kinase Inhibitors: Mitochondrial Damage and Inhibition of Glycolysis.Assay of lapatinib in murine models of cigarette smoke carcinogenesis.Mechanism-based inactivation of human cytochrome P450 3A4 by two piperazine-containing compoundsIn vitro metabolism and drug-drug interaction potential of UTL-5g, a novel chemo- and radioprotective agent.Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib.Hepatotoxicity of molecular targeted therapy.Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2.Lapatinib for advanced or metastatic breast cancerRole of biotransformation in drug-induced toxicity: influence of intra- and inter-species differences in drug metabolism.Coadministration of lapatinib increases exposure to docetaxel but not doxorubicin in the small intestine of miceNumerical analysis of time dependent inhibition kinetics: comparison between rat liver microsomes and rat hepatocyte data for mechanistic model fitting.Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients.Studies on the role of metabolic activation in tyrosine kinase inhibitor-dependent hepatotoxicity: induction of CYP3A4 enhances the cytotoxicity of lapatinib in HepaRG cellsCentral role of mitochondria in drug-induced liver injury.Drug discovery for a new generation of covalent drugs.Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors.Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review.The contributions of Sidney D. Nelson to drug metabolism research.Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.Drug-induced hepatotoxicity in cancer patients - implication for treatment.Sensitization of HER2 Positive Breast Cancer Cells to Lapatinib Using Plants-Derived Isothiocyanates.Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence.Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of LapatinibPharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients.Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction.The effects of lapatinib on CYP3A metabolism of midazolam in patients with advanced cancer.Inhibition of CYP3A4 and CYP1A2 by Aegle marmelos and its constituents.Cytochromes P450 1A2 and 3A4 Catalyze the Metabolic Activation of Sunitinib.Lapatinib-associated mucocutaneous toxicities are clinical predictors of improved progression-free survival in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer.Role of Cytochrome P450 Enzymes in the Metabolic Activation of Tyrosine Kinase Inhibitors
P2860
Q27675909-D2E924D8-C430-410A-86DF-50BBF79F6409Q28080497-CCFBE6E6-59B7-4285-94A6-CB81B4AFA697Q28818435-E7BF1FCE-A4E9-45F2-B1CB-1A842CA55AA6Q33794548-B2AD71FE-1E0E-4B90-8205-91CD4672FCC2Q34260243-EFF621B2-66D5-45A6-A105-A4E900313BDBQ34575026-55F27FA4-11BA-4915-B3A4-30E104734539Q34575031-4CEB88BC-B49E-49DB-A42E-2F449089B225Q35002433-B12CCEED-6B9F-4284-9E4B-A674E8B33728Q35648962-98FDB29D-47BA-4DD2-B754-17EC19FD6BA6Q35879839-9C58094D-6D6F-4E54-8B2C-F9AEF99EDADFQ35913209-6BE41EC7-2670-4534-A2BA-21276613185CQ36362377-664F2600-70A9-4D54-9A3C-075D13B2670EQ36411053-E2093C51-7B0B-49D5-B93D-2DB734D5EC9AQ36413309-E0246937-936E-4A37-A8F0-09282BBFA554Q36709236-F3E9F049-BCEE-423B-A4EE-09147CD743F1Q37422695-6CDEE9A8-9A82-4ADA-882C-9F5A79CD0ABDQ37926590-33C95080-911D-4F42-9CA3-99386182E181Q38011256-594930EB-9D81-492F-B65D-87B3D06892B0Q38095989-3711F012-C896-4147-9901-5A93ACA1B1CDQ38268600-A41122E1-F74A-4DE3-BE9E-62ACE00F7618Q38269782-261015C3-305F-4E1C-B7CA-312636AD7683Q38684505-182B6805-74E8-4689-8754-7D91A98E505EQ38845891-77324B7A-8E44-45A1-9CAF-0274244BB7F1Q38857859-2BF4A3C3-6998-4D21-8C19-4B45B26B4E24Q39389259-ACEE4ADF-7808-42BB-8899-AAFE537809E9Q41640449-AAB48C69-88CC-40A3-ABE5-F11C5AA8D61BQ42598708-75AE9629-6350-4CF1-A933-4FC7CD64E8E7Q45939780-0682DDA0-40E4-492E-95A4-110D7C73BEC2Q47235654-C7BD1B1D-2C35-4922-95FA-ADBF34DCCE9DQ53393752-D9E9B586-BA49-447E-B6E6-8B16CE9E3C3AQ54977664-9077631B-38C0-4DD2-95FD-B0F2630FDED1Q55070923-54BE8C7F-FDB9-41BB-85AC-AFC8D4DACD32Q58788266-C5EE1B1B-E7A3-4309-BB29-F779E7AB4917
P2860
Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib.
@ast
Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib.
@en
Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib.
@nl
type
label
Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib.
@ast
Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib.
@en
Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib.
@nl
prefLabel
Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib.
@ast
Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib.
@en
Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib.
@nl
P2093
P356
P1476
Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib.
@en
P2093
Eric Chun Yong Chan
Han Kiat Ho
Jing Wen Oh
Lee Sun New
Michelle D Wahlin
Sidney D Nelson
Woon Chien Teng
P304
P356
10.1124/MOL.110.065839
P577
2010-07-12T00:00:00Z